Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | GRM2 | Q14416 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 9/20 | 0.54 |
| ▸ | DRD4 | P21917 | 7/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752887 | 0.82 | FAAH (0.63) | FAAH | |
| SCHEMBL3759855 | 0.78 | FAAH (0.64) | FAAHDRD4 | |
| SCHEMBL3752703 | 0.78 | FAAH (0.61) | FAAH | |
| SCHEMBL3748182 | 0.78 | FAAH (0.66) | FAAH | |
| SCHEMBL3748295 | 0.78 | FAAH (0.69) | FAAHALDH1A1 | |
| SCHEMBL3743220 | 0.77 | FAAH (0.70) | FAAH | |
| SCHEMBL3751175 | 0.76 | L3MBTL1 (0.64) | FAAHDRD4KDM4EALDH1A1 | |
| SCHEMBL3747551 | 0.76 | FAAH (0.57) | FAAH | |
| SCHEMBL3747423 | 0.76 | FAAH (0.69) | FAAHALDH1A1 | |
| SCHEMBL4931423 | 0.75 | GRM2 (0.72) | GRM2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2023728-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | claimed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, APEH | FAAH 1/4885GRM2 161/4885DRD2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.